FDA and the pharmaceutical industry need to start thinking about what the new normal for clinical trials will be post-COVID-19, especially as continued social distancing restrictions reinforce the need for remote health care, representatives from FDA and Amgen say. Going forward, the clinical research community will need to ensure equal access to trials for all participants, especially with regard to technology, and figure out how to obtain informed consent in a virtual environment. The lessons learned from conducting clinical trials...